Skip to content

Pfizer stock erases all Covid gains; Should you still buy PFE?

Pfizer stock erases all Covid gains; Should you still buy PFE?

In 2021, Pfizer‘s (NYSE: PFE) shares skyrocketed as the pharmaceutical giant dominated the vaccine industry with its launch of the COVID-19 jab, more than doubling in value and reporting a staggering $37 billion in vaccine sales. 

Fast forward to 2023, and the once high-flying stock has taken a drastic turn, plummeting by nearly 40% year-to-date, according to data retrieved on October 16. 

This sharp decline has wiped out much of its pandemic-era gains, leaving investors grappling with renewed uncertainty.

PFE YTD price chart. Source: Google Finance

Why is Pfizer stock down in 2023?

During their peak in December 2021, shares of Pfizer were trading at around $60 apiece, meaning the company’s stock price has nearly halved since then.

This underperformance can largely be attributed to declining revenues in 2023, primarily due to weaker COVID-19 vaccine sales. The biotech giant thrived on the unprecedented demand for its coronavirus products in 2021 and 2022; however, as expected, that trend has significantly weakened.

Pfizer was also aware of this and said it expected 2023 to be the low point and sales of its COVID-19 products. The contribution of these offerings this year is projected to plummet around 62% year-over-year to $21.5 billion. 

PFE stock price analysis

At the time of publication, PFE was sitting at $32.11, after sliding 2.46% on Friday, October 13. 

Over the past week, the biotech company’s shares are down nearly 3%, and more than 6.1% on the month. 

At this price, PFE is trading just above a 3-year support level, located around the $31.95 mark. Losing this key threshold would pave the way for the stock to drop toward the next two supports at $30 and $26.41. 

On the upside, Pfizer faces a resistance zone between $33.3 and $34. Clearing this barrier would allow PFE to reclaim its 100-day simple moving average (SMA) at $35.96. 

PFE technical analysis chart. Source: TradingView

In the meantime, Pfizer has been on an acquisition spree lately. The New York-based drugmaker is spending a whopping $43 billion to buy the cancer treatment specialist Seagen, among other recent purchases.

Buy stocks now with Interactive Brokers – the most advanced investment platform

Disclaimer: The content on this site should not be considered investment advice. Investing is speculative. When investing, your capital is at risk.

Best Crypto Exchange for Intermediate Traders and Investors

  • Invest in 70+ cryptocurrencies and 3,000+ other assets including stocks and precious metals.

  • 0% commission on stocks - buy in bulk or just a fraction from as little as $10.

  • Copy top-performing traders in real time, automatically.

  • Regulated by financial authorities including FCA and FINRA.

2.8 Million Users
eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk. eToro USA LLC does not offer CFDs, only real Crypto assets available. Don’t invest unless you’re prepared to lose all the money you invest.

Read Next:

Weekly Finance Digest

Related posts